TCTMD’s Top 10 Most Popular Stories for January 2019
Paclitaxel-PAD worries—and pushback—dominated the list this month, along with other top hits like FDA news and TCTMD features.
Fallout from the December 2018 meta-analysis showing a late mortality signal with paclitaxel-based balloons and stents in PAD—including two paused trials, a US Food and Drug Administration “Dear Doctor” letter, and pushback from industry and investigators—continued to hold TCTMD readers’ attention this month. Other FDA activity also grabbed headlines, with yet another antihypertensive drug recall, an advisory committee meeting on the gout drug febuxostat, and a newly approved TAVR device.
Two TCTMD features rang in the new year: an exploration of veterinarian-cardiologist teamwork and our rundown of physicians’ picks for the news that rocked their fields in 2018. Other topics to make the Top 10 list for January 2019 were operator radiation exposure in relation to the rising obesity epidemic and the long-running dispute over the choice between ACE inhibitors and angiotensin receptor blockers (ARBs).
The “Dear Doctor” letter noted that the FDA is following up on a recent meta-analysis pointing to increased mortality and urges close reporting of events.
Not unlike the prior valsartan recalls, one company recalled the irbesartan lots because of contamination with a possible carcinogen.
Beloved household dogs develop many of the same structural heart diseases as people—why aren’t we fixing those to learn more about human therapy?
Major device manufacturers presented new numbers at the LINC meeting, amid news that an independent, pooled patient-level analysis is in the works.
TCTMD reporters asked a range of experts about developments that rocked their fields in 2018 and may profoundly affect patients in years to come.
The long-running dispute as to the supremacy of these two drug classes should be put to bed once and for all, say the authors of a new review.
Concerns about CV risk are prompting calls to update the label, but most panel members said the drug has a favorable risk-benefit balance.
The interventional community should be doing more to promote radiation safety during the ongoing obesity epidemic, new data suggest.
A special meeting will be held in the coming months to review the issue. The lead author says he’s pleased endovascular specialists are taking it seriously.
This latest-iteration transcatheter heart valve features design changes and a new delivery system.